410 Shares in Insulet Co. (NASDAQ:PODD) Bought by Central Pacific Bank Trust Division

Central Pacific Bank Trust Division bought a new position in shares of Insulet Co. (NASDAQ:PODDFree Report) in the 1st quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor bought 410 shares of the medical instruments supplier’s stock, valued at approximately $69,000.

Several other institutional investors and hedge funds have also modified their holdings of PODD. Wolff Wiese Magana LLC boosted its stake in shares of Insulet by 2,680.0% in the 4th quarter. Wolff Wiese Magana LLC now owns 139 shares of the medical instruments supplier’s stock valued at $30,000 after purchasing an additional 134 shares in the last quarter. Benjamin F. Edwards & Company Inc. acquired a new stake in Insulet during the 4th quarter worth approximately $34,000. Sunbelt Securities Inc. bought a new stake in Insulet during the 1st quarter worth approximately $29,000. Jones Financial Companies Lllp acquired a new position in Insulet in the 4th quarter valued at approximately $40,000. Finally, Lindbrook Capital LLC lifted its holdings in shares of Insulet by 64.1% during the fourth quarter. Lindbrook Capital LLC now owns 192 shares of the medical instruments supplier’s stock worth $42,000 after purchasing an additional 75 shares during the period.

Insider Buying and Selling

In other Insulet news, Director Timothy J. Scannell sold 3,300 shares of the company’s stock in a transaction that occurred on Tuesday, May 28th. The stock was sold at an average price of $180.90, for a total value of $596,970.00. Following the completion of the transaction, the director now directly owns 42,586 shares in the company, valued at approximately $7,703,807.40. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. In other Insulet news, Director Timothy J. Scannell sold 3,300 shares of the company’s stock in a transaction that occurred on Tuesday, May 28th. The stock was sold at an average price of $180.90, for a total transaction of $596,970.00. Following the sale, the director now directly owns 42,586 shares in the company, valued at $7,703,807.40. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, SVP Mark N. Field sold 1,500 shares of Insulet stock in a transaction dated Friday, June 14th. The stock was sold at an average price of $199.96, for a total transaction of $299,940.00. Following the transaction, the senior vice president now directly owns 12,875 shares of the company’s stock, valued at $2,574,485. The disclosure for this sale can be found here. In the last three months, insiders have sold 13,931 shares of company stock valued at $2,636,286. 0.47% of the stock is owned by company insiders.

Analyst Ratings Changes

A number of research analysts have recently issued reports on the company. Wolfe Research raised Insulet from a “peer perform” rating to an “outperform” rating and set a $200.00 price objective on the stock in a research note on Tuesday, May 7th. Barclays decreased their price target on shares of Insulet from $213.00 to $200.00 and set an “equal weight” rating for the company in a research note on Monday, May 13th. Canaccord Genuity Group upped their price objective on shares of Insulet from $226.00 to $234.00 and gave the stock a “buy” rating in a report on Friday, May 10th. Raymond James lowered their price objective on Insulet from $218.00 to $213.00 and set an “outperform” rating for the company in a research note on Friday, May 10th. Finally, Redburn Atlantic assumed coverage on Insulet in a research note on Thursday, May 30th. They set a “buy” rating and a $235.00 target price on the stock. Four investment analysts have rated the stock with a hold rating and fifteen have given a buy rating to the company’s stock. Based on data from MarketBeat, Insulet has a consensus rating of “Moderate Buy” and an average target price of $239.18.

View Our Latest Stock Analysis on Insulet

Insulet Trading Up 1.3 %

Insulet stock opened at $197.67 on Thursday. The business’s fifty day simple moving average is $188.26 and its two-hundred day simple moving average is $185.70. The company has a current ratio of 3.74, a quick ratio of 2.75 and a debt-to-equity ratio of 1.72. The company has a market capitalization of $13.84 billion, a price-to-earnings ratio of 59.90, a price-to-earnings-growth ratio of 3.58 and a beta of 1.16. Insulet Co. has a 12 month low of $125.82 and a 12 month high of $293.64.

Insulet (NASDAQ:PODDGet Free Report) last announced its quarterly earnings data on Thursday, May 9th. The medical instruments supplier reported $0.73 earnings per share for the quarter, topping analysts’ consensus estimates of $0.39 by $0.34. The company had revenue of $441.70 million during the quarter, compared to analyst estimates of $424.05 million. Insulet had a net margin of 13.14% and a return on equity of 34.06%. The firm’s revenue for the quarter was up 23.3% on a year-over-year basis. During the same period in the previous year, the business earned $0.23 EPS. As a group, equities analysts predict that Insulet Co. will post 3.11 earnings per share for the current fiscal year.

About Insulet

(Free Report)

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.

Further Reading

Want to see what other hedge funds are holding PODD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Insulet Co. (NASDAQ:PODDFree Report).

Institutional Ownership by Quarter for Insulet (NASDAQ:PODD)

Receive News & Ratings for Insulet Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Insulet and related companies with MarketBeat.com's FREE daily email newsletter.